[go: up one dir, main page]

MX2018010065A - Forma de dosificacion oral que comprende rifaximina en forma beta. - Google Patents

Forma de dosificacion oral que comprende rifaximina en forma beta.

Info

Publication number
MX2018010065A
MX2018010065A MX2018010065A MX2018010065A MX2018010065A MX 2018010065 A MX2018010065 A MX 2018010065A MX 2018010065 A MX2018010065 A MX 2018010065A MX 2018010065 A MX2018010065 A MX 2018010065A MX 2018010065 A MX2018010065 A MX 2018010065A
Authority
MX
Mexico
Prior art keywords
oral dosage
dosage form
rifaximin
beta
relates
Prior art date
Application number
MX2018010065A
Other languages
English (en)
Inventor
Xaver Schwarz Franz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018010065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of MX2018010065A publication Critical patent/MX2018010065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a una forma de dosificación oral que contiene rifaximina en una forma beta, en donde la forma de dosificación oral proporciona una liberación retardada del agente farmacéutico activo. Además, la invención se refiere a la preparación de una forma de dosificación oral, de preferencia de una tableta.
MX2018010065A 2017-04-26 2018-04-25 Forma de dosificacion oral que comprende rifaximina en forma beta. MX2018010065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168281 2017-04-26
PCT/EP2018/060547 WO2018197538A1 (en) 2017-04-26 2018-04-25 Oral dosage form comprising rifaximin in form beta

Publications (1)

Publication Number Publication Date
MX2018010065A true MX2018010065A (es) 2019-02-07

Family

ID=58632906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010065A MX2018010065A (es) 2017-04-26 2018-04-25 Forma de dosificacion oral que comprende rifaximina en forma beta.

Country Status (9)

Country Link
US (1) US11052071B2 (es)
EP (1) EP3416627B9 (es)
AU (1) AU2018211305B2 (es)
CA (1) CA3013161C (es)
ES (1) ES2774553T3 (es)
MX (1) MX2018010065A (es)
PL (1) PL3416627T3 (es)
SI (1) SI3416627T1 (es)
WO (1) WO2018197538A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
KR20210105381A (ko) * 2018-12-19 2021-08-26 프리울켐 에스.피.에이. 리팍시민 정제의 제조 방법 및 리팍시민 정제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US7252497B2 (en) 2005-03-10 2007-08-07 Husky Injection Molding Systems Ltd. Post-molding molded article conditioning apparatus with a selectively controlled transfer flow structure
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
PT2294012E (pt) * 2008-05-07 2014-10-15 Salix Pharmaceuticals Ltd Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal
CN101653428A (zh) * 2008-08-18 2010-02-24 北京瑞伊人科技发展有限公司 利福昔明肠溶制剂组合物及其制备方法
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas

Also Published As

Publication number Publication date
EP3416627A1 (en) 2018-12-26
WO2018197538A1 (en) 2018-11-01
EP3416627B9 (en) 2020-04-22
US20190388404A1 (en) 2019-12-26
CA3013161A1 (en) 2018-10-26
US11052071B2 (en) 2021-07-06
ES2774553T3 (es) 2020-07-21
CA3013161C (en) 2020-03-24
PL3416627T3 (pl) 2020-06-01
AU2018211305A1 (en) 2018-11-15
SI3416627T1 (sl) 2020-03-31
EP3416627B1 (en) 2019-11-27
AU2018211305B2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IN2015DN03984A (es)
MX2017016802A (es) Formulaciones farmaceuticas.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
PH12014501408A1 (en) Immediate release multi unit pellet system
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12013502325A1 (en) Drug delivery system
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
IL280376A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
IL272806A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.

Legal Events

Date Code Title Description
FG Grant or registration